Clinical advances and challenges of anti-angiogenic targeted therapy in gastric cancer.

Front Oncol · 2025 · PMC12588871 · PMID 41211418

Europe PMC DOI

hedged sentences

0.6757

closest p · 13.5× alpha

0.6757

boldest claim

The sentences

did not reach statistical significancep=0.6757not close (p > 0.1)

However, the improvement in mOS did not reach statistical significance (11.2 months vs. 10.7 months, p=0.6757).

also in 111,027 other papers

a positive trendno p-value reported

Although there was a positive trend in OS, the combination therapy did not reach the pre-specified primary endpoint ( 111 ).In the exploration of first-line therapy, a prospective phase I trial in in 2013 determined the Maximum Tolerable Dose (MTD) of sunitinib in combination with FOLFIRI to be 25 mg/day ( 112 ).

also in 11,005 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.